Open AccessIn vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses
Author(s) -
Kulshrestha Arpita,
Katara Gajendra K.,
Ibrahim Safaa A.,
Riehl Valerie E.,
Schneiderman Sylvia,
Bilal Mahmood,
Young Alexandria N.,
Levine Shayna,
Fleetwood Sara,
Dolan James,
GilmanSachs Alice,
Beaman Kenneth D.
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12782
Subject(s) - in vivo , ovarian cancer , chemistry , monoclonal antibody , cancer research , ovarian tumor , antibody , immune system , cancer cell , in vitro , cancer , biology , biochemistry , medicine , immunology , microbiology and biotechnology
Tumor acidity is the key metabolic feature promoting cancer progression by eliciting immune‐suppression. V‐ATPases on a cancer cell's surface pump out excess protons and acidify the tumor microenvironment (TME). In vivo treatment of ovarian tumors using a monoclonal antibody (a2v‐mAb) directed against V‐ATPase‐V0a2 delays tumor growth by enhancing antitumor immune responses, making it an effective treatment strategy in ovarian cancer.